TScan Therapeutics, Inc. Common Stock TCRX
Analyst Ratings
- Consensus
- Buy — 3 Buy · 1 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $6.00 (+670.4% upside)
Key Stats
- Today's Range
- $0.74 – $0.79
- 50-Day Range
- $0.72 – $1.28
- 52-Week Range
- $0.72 – $2.57
- Volume
- 278K shs
- Average Volume
- 658K shs
- Market Cap
- $52.39 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 0.76
- Price / Sales
- 7.37
Short Interest
- Short Interest
- 0.01%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $7.11 million
- Net Income
- $-117,712,000
- Net Margin
- -1655.35%
- Return on Equity
- -170.55%
- Debt-to-Equity
- 0.47
About TScan Therapeutics, Inc. Common Stock
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Related Stocks
Compare head-to-head: TCRX vs AMGN·TCRX vs HALO·TCRX vs KYMR·TCRX vs RGEN
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.